FY2027 Earnings Estimate for THTX Issued By Leede Financial

Theratechnologies Inc. (NASDAQ:THTX) – Leede Financial issued their FY2027 EPS estimates for shares of Theratechnologies in a research note issued to investors on Wednesday, February 26th. Leede Financial analyst D. Loe forecasts that the company will earn $0.23 per share for the year. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.23 EPS.

Separately, Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Stock Up 1.9 %

Shares of NASDAQ:THTX opened at $1.65 on Friday. The firm has a fifty day moving average of $1.74 and a two-hundred day moving average of $1.45. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.18. The firm has a market capitalization of $75.87 million, a P/E ratio of -16.50 and a beta of 1.26.

Institutional Investors Weigh In On Theratechnologies

Institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Theratechnologies during the fourth quarter valued at approximately $27,000. Bank of America Corp DE increased its stake in shares of Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after purchasing an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Theratechnologies during the 4th quarter valued at $33,000. BNP Paribas Financial Markets acquired a new stake in shares of Theratechnologies in the 4th quarter valued at $36,000. Finally, Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the 4th quarter valued at $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.